Conference Coverage

A unique care model for comorbid depression, PTSD


 

FROM ASCP 2022

A model for other settings?

Commenting on the study, Nagy A. Youssef, MD, PhD, professor of psychiatry and director of clinical research at Ohio State University, Columbus, called the results “interesting.”

“Treating patients with comorbid mild to moderate depression and current or past PTSD within the primary care setting using a care management program could be a model for other VA hospitals as well as in non-VA settings,” said Dr. Youssef, who was not part of the study.

Dr. Youssef noted that not only was there no difference in symptomatic improvement between the depression-plus-PTSD and depression-only groups, but program completion rates did not differ.

This further emphasizes “the potential utility of this approach in initial patient treatment, especially with limited mental health resources and the need to help more patients,” he said.

Dr. Zuschlag and Dr. Youssef report no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Antipsychotic safe, effective for resistant depression in phase 3 trial
Federal Practitioner
Long COVID neuropsychiatric deficits greater than expected
Federal Practitioner
Refugees have a high burden of chronic pain associated with mental illness
Federal Practitioner
Antipsychotic tied to dose-related weight gain, higher cholesterol
Federal Practitioner
Novel drug ‘promising’ for concomitant depression, insomnia
Federal Practitioner
Genetic testing for best antidepressant accurate, cost effective
Federal Practitioner
When suffering defies diagnosis
Federal Practitioner
Adjunctive psychotherapy may offer no benefit in severe depression
Federal Practitioner
New onset-depression after RA diagnosis raises mortality risk ‘more than sixfold’
Federal Practitioner
Psychedelic drugs ‘truly have potential’ in headache care
Federal Practitioner